Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantrex-3 claims

This article was originally published in The Tan Sheet

Executive Summary

Electronic Retailing Self-Regulation Program will refer advertising for Basic Research's Zantrex-3 to the Federal Trade Commission because the firm "did not substantively address the core claims" cited in ERSRP's inquiry, the National Advertising Review Council group says Oct. 20. The request for substantiation was part of ERSRP's routine monitoring program. Zantrex-3 is an ephedra-free weight-loss supplement that claims to provide "546% more weight loss than the leading ephedrine-based diet pill," according to the product's 1website...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS097441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel